Anti-GALE antibody [EPR11089(B)] (ab155277)
- Datasheet
- References
- Protocols
Overview
-
Product nameAnti-GALE antibody [EPR11089(B)]
See all GALE primary antibodies -
DescriptionRabbit monoclonal [EPR11089(B)] to GALE
-
Host speciesRabbit
-
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: Flow Cyt,ICC or IHC-P -
Species reactivityReacts with: Rat, Human
-
Immunogen
A synthetic peptide corresponding to residues in Human GALE was (UniProt ID: Q14376).
-
Positive control
- Human fetal liver, HT29 and HepG2 lysates.
-
General notes
Mouse: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
-
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant -
PurityTissue culture supernatant
-
ClonalityMonoclonal
-
Clone numberEPR11089(B)
-
IsotypeIgG
-
Research areas
Associated products
-
Isotype control
-
Positive Controls
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab155277 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | 1/1000 - 1/10000. Predicted molecular weight: 38 kDa. | |
| IP | 1/10 - 1/100. |
Target
-
FunctionCatalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine.
-
PathwayCarbohydrate metabolism; galactose metabolism.
-
Involvement in diseaseDefects in GALE are the cause of epimerase-deficiency galactosemia (EDG) [MIM:230350]; also known as galactosemia type 3. Clinical features include early-onset cataracts, liver damage, deafness and mental retardation. There are two clinically distinct forms of EDG. (1) A benign, or 'peripheral' form with no detectable GALE activity in red blood cells and characterized by mild symptoms. Some patients may suffer no symptoms beyond raised levels of galactose-1-phosphate in the blood. (2) A much rarer 'generalized' form with undetectable levels of GALE activity in all tissues and resulting in severe features such as restricted growth and mental development.
-
Sequence similaritiesBelongs to the sugar epimerase family.
- Information by UniProt
-
Database links
- Entrez Gene: 2582 Human
- Entrez Gene: 114860 Rat
- Omim: 606953 Human
- SwissProt: Q14376 Human
- SwissProt: P18645 Rat
- Unigene: 632380 Human
- Unigene: 29908 Rat
-
Alternative names
- FLJ95174 antibody
- FLJ97302 antibody
- Galactose 4 epimerase UDP antibody
see all
Images
-
![Western blot - Anti-GALE antibody [EPR11089(B)] (ab155277)](https://www.abcam.com/ps/products/155/ab155277/Images/GALE-Primary-antibodies-ab155277-1.jpg)
Western blot - Anti-GALE antibody [EPR11089(B)] (ab155277)All lanes : Anti-GALE antibody [EPR11089(B)] (ab155277) at 1/1000 dilution
Lane 1 : Human fetal liver lysate
Lane 2 : HT29 lysate
Lane 3 : HepG2 lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 38 kDa
Datasheets and documents
References
ab155277 has not yet been referenced specifically in any publications.
